Account
Orders
Advanced search
Discovery and Development of an Anthelmintic Drug
Louise Reader
Read on Louise Reader App.
This open-access book provides a comprehensive reference on the discovery and development of praziquantel. It presents the full research and development (R&D) journey of this essential anthelmintic drug, combining foundational science with practical insights.
The book covers a wide range of topics, including a brief history of pharmaceutical industry, unmet medical needs, parasitic flatworm biology, and strategies for schistosomiasis control and elimination. Both human and animal health applications are addressed. Additional chapters explore chemical and manufacturing aspects, drug targets, biomarkers, toxicology, clinical efficacy, regulatory pathways, and Intellectual Property considerations. Rich illustrations, expert commentary, and clear summaries enhance the educational value of the text.
Designed for students, academics, and industry professionals alike, this volume serves as a valuable addition to any scientific library. It also supports the United Nations Sustainable Development Goal 3 (Good Health and Well-being) by contributing to the global fight against schistosomiasis and other Neglected Tropical Diseases.
Les livres numériques peuvent être téléchargés depuis l'ebookstore Numilog ou directement depuis une tablette ou smartphone.
PDF : format reprenant la maquette originale du livre ; lecture recommandée sur ordinateur et tablette EPUB : format de texte repositionnable ; lecture sur tous supports (ordinateur, tablette, smartphone, liseuse)
DRM Adobe LCP
LCP DRM Adobe
This ebook is DRM protected.
LCP system provides a simplified access to ebooks: an activation key associated with your customer account allows you to open them immediately.
ebooks downloaded with LCP system can be read on:
Adobe DRM associates a file with a personal account (Adobe ID). Once your reading device is activated with your Adobe ID, your ebook can be opened with any compatible reading application.
ebooks downloaded with Adobe DRM can be read on:
mobile-and-tablet To check the compatibility with your devices,see help page
Thomas Spangenberg, PhD - With Merck since 2015, Thomas is heading global health research and leads drug discovery programs from drug screening to preclinical candidate nomination. He drives translation research by generating Real-World Data to support clinical candidates and catalyses research in infectious diseases through open innovation initiatives. Prior to joining Merck, Thomas was part of the drug discovery team at non-for-profit R&D organization Medicines for Malaria Venture (Switzerland), where he led the open-source Malaria Box and Pathogen Box initiatives aimed at accelerating drug discovery for infectious diseases.
Thomas holds a PhD in organic chemistry from the Universities of Strasbourg (France) and Freiburg im Breisgau (Germany). In 2009, he became a post-doctoral fellow at Harvard University (USA), contributing to the total synthesis of mycolactones and advancing point-of-care diagnostics for Buruli ulcer, a neglected necrotizing skin disease. He has authored and co-authored over 50 peer-reviewed articles and is a co-inventor on several patents.
Sign up to get our latest ebook recommendations and special offers